|
|
Technical University of Denmark, Building 207
Lyngby, DK-2800 Denmark
phone:(+45) 45252400
fax:(+45) 45252431
|
|
| Symbol |
Private |
| Founded |
2001 |
| Employees |
|
|
|
| www.liplasome.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Novel drug-delivery strategies for the field of oncology. |
|
| Management |
| Palle Schelde, Chief Executive Officer (CEO); Mogens Winkel Madsen, PhD, Chief Scientific Officer (CSO); Morten J. Petersen, Director, Drug Development; Vibeke Ehlig-Jensen,
Assistant to Management
|
| |
|
|
| |
|
| Keywords |
| drugs, delivery, lipids, nanotechnology, particles, oncology, inflammation cancer |
|
|
|
| Description |
|
LiPlasome Pharma is focused on novel drug-delivery strategies in the field of oncology. |
|
| Technology / Differentiation |
| LiPlasome Pharma's drug-delivery platform is based on recent scientific discoveries and inventions within lipid-based drug transporting nano-particles. |
|
|
| Strategy |
Development of the targeted drug delivery platform for conventional chemotherapeutics like doxorubicin and cisplatin. The purpose is to introduce a reformulated product with a significantly improved therapeutic index compared to what is already available of both plain formulations and liposome formulated drugs.
Development of the targeted prodrug delivery platform for a new class of anticancer drugs called anticancer lysolipids. These promising anticancer lipids have been known for a long time, but have never been applied systemically in the clinic due to severe side effects like hemolysis of red blood cells.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members